Celularity Inc. is a biotechnology company that specializes in developing innovative cellular therapies to address various medical conditions and diseases. Founded in 2017 and headquartered in Florham Park, New Jersey, Celularity focuses on harnessing the potential of placental-derived cells and tissues to create cutting-edge treatments.
At the heart of Celularity's approach is its proprietary platform technology that utilizes placental-derived cells, which are rich in regenerative properties and immune-modulatory capabilities. The company aims to leverage these unique cellular resources to develop advanced therapies across multiple therapeutic areas, including oncology, immune disorders, and degenerative diseases.
Celularity's pipeline includes a range of investigational therapies that are designed to target specific medical challenges. One notable example is the development of cellular immunotherapies to combat cancer, harnessing the power of natural killer (NK) cells and other immune cells to enhance the body's ability to fight tumors.
Through strategic partnerships, research collaborations, and in-house expertise, Celularity is advancing the field of cellular medicine. The company's innovative approach has garnered attention from both the medical and investment communities, positioning Celularity as a promising player in the biotechnology sector.
The company's dedication to scientific rigor and clinical validation underscores its commitment to bringing safe and effective treatments to patients in need. By harnessing the potential of placental-derived cells, Celularity is working towards transforming the landscape of healthcare by providing novel cellular therapies that have the potential to address significant unmet medical needs.